| Literature DB >> 25729162 |
Wei Xu1, Da-Wei Chen2, Yan-Bin Jin2, Zhen-Jun Dong3, Wei-Jiang Zhang4, Jin-Wen Chen2, Shu-Mei Yang2, Jian-Rong Wang5.
Abstract
[Purpose] The aim of this study was to determine fall incidence and explore clinical factors of falls among older Chinese veterans in military communities.Entities:
Keywords: Clinical factors; Falls; Incidence
Year: 2015 PMID: 25729162 PMCID: PMC4339132 DOI: 10.1589/jpts.27.331
Source DB: PubMed Journal: J Phys Ther Sci ISSN: 0915-5287
Fig. 1.Flowchart for subjects. The baseline sample was 466 subjects. During the 12-month follow-up, 10 subjects dropped out. Thirteen subjects died; three of these subjects experienced 1 fall and 1 experienced. 2 falls before they died. The final sample was 447 older veterans.
Demographic characteristics and health status for all subjects, non-fallers and fallers
| Variables | Total (n=447) | Non-fallers (n= 336) | Fallers (n=111 ) | |||
|---|---|---|---|---|---|---|
| Mean±SD | Number | Mean±SD | Number | Mean±SD | Number | |
| Demographic characteristics | ||||||
| Age (y) | 82.2±4.7 (60–95) | 81.8±4.8 (60–94) | 83.6±4.0*** (74–95) | |||
| Gender (male) | 417 (93.3) | 315 (93.8) | 102 (91.9) | |||
| Physical measurements | ||||||
| SBP (mmHg) | 136.7±18.2 (90–210) | 137.9±18.8 (90–210) | 131.0±16.5 (83–170) | |||
| DBP (mmHg) | 71.5±9.9 (48–100) | 72.5±9.8 (48–100) | 67.2±8.3* (50–90) | |||
| BMI (kg/m2) | ||||||
| <18.5 | 10 (2.2) | 9 (2.7) | 1 (0.9) | |||
| 18.5–25 | 216 (48.3) | 165 (49.1) | 51 (45.9) | |||
| >25 | 221 (49.4) | 162 (48.2) | 59 (53.2) | |||
| Visual acuity | 0.8±0.3 (0.0–1.5) | 0.8±0.3 (0.0–1.5) | 0.7±2.3*** (0.0–1.2) | |||
| Hearing acuity | ||||||
| Normal | 362 (81.0) | 281 (83.6) | 81 (73.0) | |||
| Slight impairment | 23 (5.1) | 15 (4.5) | 8 (7.2)** | |||
| Modest impairment | 28 (6.3) | 22 (6.5) | 6 (5.4) | |||
| Severe impairment | 34 (7.6) | 18 (5.4) | 16 (14.4) | |||
| FRSTS test score | ||||||
| 1 | 90 (20.1) | 77 (22.9) | 13 (11.7) | |||
| 2 | 160 (35.8) | 134 (39.9) | 26 (23.4) | |||
| 3 | 80 (17.9) | 63 (18.8) | 17 (15.3)*** | |||
| 4 | 79 (17.7) | 45 (13.4) | 34 (30.6) | |||
| 5 | 38 (8.5) | 17 (5.1) | 21 (18.9) | |||
| Chronic diseases | ||||||
| Dementia | 29 (6.5) | 14 (4.2) | 15 (13.5)** | |||
| Parkinsonism | 26 (5.8) | 14 (4.2) | 12 (10.8)* | |||
| Stroke | 44 (9.8) | 14 (4.2) | 30 (27.0)*** | |||
| Cervical diseases | 103 (23.0) | 73 (21.7) | 30 (27.0) | |||
| Lumbar diseases | 97 (21.7) | 65 (19.3) | 32 (28.8)* | |||
| Knee diseases | 96 (21.5) | 67 (19.9) | 29 (26.1) | |||
| Coronary disease | 312 (69.8) | 224 (66.7) | 88 (79.3)* | |||
| Sinus bradycardia | 70 (15.7) | 52 (15.5) | 18 (16.2) | |||
| Atrial fibrillation | 48 (10.7) | 36 (10.7) | 12 (10.8) | |||
| Atrioventricular block | 79 (17.7) | 58 (17.3) | 21 (18.9) | |||
| CHF | 30 (6.7) | 23 (6.8) | 7 (6.3) | |||
| Hypertension | 276 (61.7) | 207 (61.6) | 69 (62.2) | |||
| Diabetes mellitus | 123 (27.9) | 88 (26.2) | 35 (31.5) | |||
| COPD | 19 (4.3) | 15 (4.5) | 4 (3.6) | |||
| SAS | 11 (2.5) | 7 (2.1) | 4 (3.6) | |||
| CRF | 40 (8.9) | 25 (7.4) | 15 (13.5) | |||
| Hyperlipemia | 119 (26.6) | 86 (25.6) | 33 (29.7) | |||
| Hyperuricemia | 106 (23.7) | 85 (25.3) | 21 (18.9) | |||
| Cancer | 74 (16.6) | 53 (15.8) | 21 (18.9) | |||
| Anemia | 22 (4.9) | 14 (4.2) | 8 (7.2) | |||
| Multiple diseases | ||||||
| ≤1 | 62 (13.9) | 50 (14.9) | 12 (10.8) | |||
| 2–4 | 282 (63.1) | 227 (67.6) | 55 (49.5)*** | |||
| ≥5 | 103 (23.0) | 59 (17.6) | 44 (39.6) | |||
| Medication use | ||||||
| Sedatives | 42 (9.4) | 22 (6.5) | 20 (18.0)*** | |||
| Antihypertensives | 209 (46.8) | 149 (44.3) | 60 (54.1) | |||
| Antiarrhythmics | 67 (15.0) | 51 (15.2) | 16 (14.4) | |||
| Antidepressants | 6 (1.3) | 5 (1.5) | 1 (0.9) | |||
| Oral hypoglycemics | 79 (17.7) | 53 (15.8) | 26 (23.4) | |||
| Multiple medications | ||||||
| ≤5 | 279 (62.4) | 226 (67.3) | 53 (47.7) | |||
| 6–9 | 135 (30.2) | 93 (27.7) | 42 (37.8)*** | |||
| ≥10 | 33 (7.4) | 17 (5.1) | 16 (14.4) | |||
| Chemical measurements | ||||||
| Hemoglobin (g/L) | 132.2±14.2 (76–194) | 133.0±14.2 (76–194) | 130.0±13.9 (95–164) | |||
| Albumin (g/L) | 42.8±2.6 (16.3–50.0) | 42.9±2.7 (16.3–50.0) | 42.5±2.3 (36.0–48.0) | |||
| Total protein (g/L) | 68.9±4.4 (55.-80.0) | 69.0±4.4 (55.0–80.0) | 68.8±4.6 (59.6–79.0) | |||
| Blood urea nitrogen (mmol/L) | 6.4±2.2 (2.6–25.4) | 6.4±2.2 (2.9–25.4) | 6.4±2.3 (2.6–17.3) | |||
| Urinary creatine (mmol/L) | 85.5±28.9 (33–382) | 85.2±28.4 (33–382) | 86.2±30.4 (39–252) | |||
| Uric acid (mmol/L) | 347.3±80.7 (154–675) | 347.2±82.1 (158–675) | 347.8±76.6 (154–670) | |||
| Fasting blood sugar (mmol/L) | 5.4±1.3 (3.2–15.1) | 5.4±1.2 (3.2–15.1) | 5.5±1.5 (4.0–13.1) | |||
| Total cholesterol (mmol/L) | 4.5±0.8 (1.1–7.5) | 4.5±0.8 (1.1–7.6) | 4.5±0.8 (2.2–6.9) | |||
| Triglyceride (mmol/L) | 1.4±0.9 (0.3–9.5) | 1.5±0.9 (0.3–9.5) | 1.4±0.8 (0.4–5.2) | |||
| LDL (mmol/L) | 2.8±0.7 (1.1–5.4) | 2.8±0.7 (1.1–5.4) | 2.7±0.7 (1.1–4.7) | |||
| HDL (mmol/L) | 1.2±0.4 (0.7–4.3) | 1.2±0.4 (0.7–4.3) | 1.2±0.3 (0.7–2.4) | |||
| Others | ||||||
| Assistive device use | 122 (27.3) | 74 (22.0) | 48 (43.2)*** | |||
| Falls history (the past 6 months) | 67 (15.0) | 30 (8.9) | 37 (33.3)*** | |||
SBP: systolic blood pressure; DBP: diastolic blood pressure; FRSTS test: five repetition sit-to-stand test; CHF: chronic heart failure; COPD: chronic obstructive pulmonary disease; SAS: sleep apnea syndrome; CRF: chronic renal failure; LDL: low density lipoproteins; HDL: high density lipoproteins. * p<0.05; **p<0.01; ***p<0.001
Comparison of the sample distribution and the incidence of falls and fallers between Hong Kong and the present study
| Age (y) | Sample distribution | Fall incidence | Faller incidence | |||
|---|---|---|---|---|---|---|
| Hong Kong % (n) | Present study % (n) | Hong Kong (/1,000 PY) | Present study (/1,000 PY) | Hong Kong (/1,000 PY) | Present study (/1,000 PY) | |
| 60–64 | / | 1.1 (5) | / | 0 | / | 0 |
| 65–69 | 33.9 (514) | 1.1 (5) | 167 | 0 | 132 | 0 |
| 70–74 | 29.1 (441) | 1.8 (8) | 248 | 125 | 173 | 125 |
| 75–79 | 19.2 (291) | 14.5 (65) | 363 | 200 | 254 | 154 |
| 80–84 | 12.5 (189) | 55.3 (247) | 387 | 328 | 285 | 239 |
| 85+ | 5.4 (82) | 26.2 (117) | 468 | 491 | 351 | 357 |
| 85–89 | / | 20.8 (93) | / | 510 | / | 347 |
| 90+ | / | 5.4 (24) | / | 421 | / | 379 |
| All | 100 (1517) | 100 (447) | 270 | 342 | 198 | 249 |
| Standardized incidence | 1964 | 1964 | 300 | 187 | 219 | 146 |
The incidence of falls was calculated as the number of falls divided per 1,000 person-years. The incidence of fallers was calculated as the number of fallers divided per 1,000 person-years. A slash(/) means no investigation.
Cox regression analyses of clinical independent risk factors for falls
| Variables | Model 1 | Model 2 | Model 3 | |||
|---|---|---|---|---|---|---|
| RR | 95% CI | RR | 95% CI | RR | 95% CI | |
| Demographic characteristics | ||||||
| Age | 1.08 | 1.04–1.13*** | 1.03 | 0.98–1.08 | ||
| Sex | 1.37 | 0.70–2.72 | 1.20 | 0.58–2.47 | ||
| Physical measurements | ||||||
| SBP (mmHg) | 0.99 | 0.98–1.00* | 0.99 | 0.98–1.00 | ||
| DBP (mmHg) | 0.98 | 0.96–1.00* | 0.98 | 0.95–1.08 | ||
| Visual acuity | 0.36 | 0.18–0.71** | 0.47 | 0.23–0.96* | ||
| Hearing acuity | 0.83 | 0.70–0.99* | 0.85 | 0.71–1.02 | ||
| BMI (kg/m2) | ||||||
| <18.5 vs.18.5–25 | 3.94 | 0.52–29.64 | ||||
| >25.0 vs. 18.5–25 | 1.16 | 0.79–1.70 | ||||
| Chronic diseases | ||||||
| Dementia | 2.20 | 1.25–3.87** | 1.55 | 0.83–2.90 | ||
| Parkinsonism | 2.21 | 1.21–4.03* | 1.41 | 0.72–2.75 | ||
| Stroke | 4.39 | 2.87–6.70*** | 2.43 | 1.51–3.93*** | ||
| Cervical diseases | 1.29 | 0.85–1.97 | ||||
| Lumbar diseases | 1.60 | 1.06–2.41* | 1.73 | 1.12–2.70* | ||
| Knee diseases | 1.30 | 0.85–1.99 | ||||
| Coronary diseases | 1.55 | 0.97–2.49 | ||||
| Sinus bradycardia | 1.04 | 0.63–1.72 | ||||
| Atrial fibrillation | 1.02 | 0.56–1.86 | ||||
| Atrioventricular block | 1.01 | 0.62–1.63 | ||||
| CHF | 0.75 | 0.31–1.64 | ||||
| Hypertension | 0.94 | 0.61–1.38 | ||||
| Diabetes mellitus | 1.22 | 0.82–1.83 | ||||
| COPD | 0.70 | 0.26–1.90 | ||||
| SAS | 1.99 | 0.73–5.43 | ||||
| CRF | 1.44 | 0.82–2.52 | ||||
| Hyperlipemia | 1.16 | 0.77–1.75 | ||||
| Hyperuricemia | 0.77 | 0.48–1.24 | ||||
| Cancer | 1.16 | 0.72–1.86 | ||||
| Anemia | 1.32 | 0.64–2.74 | ||||
| Medication use | ||||||
| Sedatives | 2.19 | 1.34–3.59** | 1.80 | 1.05–3.08* | ||
| Antihypertensives | 1.27 | 0.87–1.85 | ||||
| Antiarrhythmics | 0.90 | 0.49–1.66 | ||||
| Antidepressants | 0.92 | 0.54–1.56 | ||||
| Oral hypoglycemics | 1.49 | 0.96–2.31 | ||||
| Chemical measurements | ||||||
| Hemoglobin (g/L) | 0.99 | 0.98–1.01 | ||||
| Albumin (g/L) | 0.97 | 0.91–1.04 | ||||
| Total protein (g/L) | 0.99 | 0.95–1.03 | ||||
| Blood urea nitrogen (g/L) | 0.98 | 0.89–1.07 | ||||
| Urinary creatinine (mmol/L) | 1.00 | 0.99–1.01 | ||||
| Uric acid (mmol/L) | 1.00 | 0.99–1.00 | ||||
| Fasting blood sugar (mmol/L) | 1.08 | 0.95–1.22 | ||||
| Total cholesterol (mmol/L) | 1.00 | 0.80–1.24 | ||||
| Triglyceride (mmol/L) | 1.00 | 0.80–1.24 | ||||
| LDL (mmol/L) | 0.97 | 0.75–1.26 | ||||
| HDL (mmol/L) | 1.00 | 0.59–1.68 | ||||
| Assistive device use | 0.51 | 0.34–0.77** | 1.28 | 0.82–2.01 | ||
| History of falls (past 6 months) | 3.28 | 2.19–4.91*** | 2.77 | 1.78–4.32*** | ||
RR: relative risk; CI: confidence interval; SBP: systolic blood pressure; DBP: diastolic blood pressure; FRSTS test: five-repetition sit-to-stand test; CHF: chronic heart failure; COPD: chronic obstructive pulmonary disease; SAS: sleep apnea syndrome; CRF: chronic renal failure. In model 1, only demographic data were included. In model 2, after adjustment for demographics, all variables of physical measurements, chronic diseases, medication use, chemical measurements of blood, assistive device use, and fall history were examined, respectively. In model 3, after adjustment for demographics, all significant variables in model 2 were simultaneously entered into a “summary” Cox regression model. *p<0.05; **p<0.01; ***p<0.001
Relationship between assistive device use and physical function score
| Variable | Physical function score | |||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | ||
| Without assistive device | Count | 84 | 137 | 57 | 36 | 11 |
| % within physical function | 93.3% | 85.6% | 71.3% | 45.6% | 28.9% | |
| With assistive device | Count | 6 | 23 | 23 | 43 | 27 |
| % within physical function | 6.7% | 14.4% | 28.8% | 54.4% | 71.1% | |
A score of 1 was>0 s but ≤9 s in the five-repetition sit-to-stand test, a score of 2 was >9 s but ≤12 s in the five-repetition sit-to-stand test, a score of 3 was>12 s but ≤15 s in the five-repetition sit-to-stand test, a score of 4 was>15 s in the five-repetition sit-to-stand test, and a score of 5 was unable to complete the five-repetition sit-to-stand test.